EPIX - ESSA Pharma Inc.
| Previous Close | 3.8000 |
| Open | 4.0000 |
| Bid | 3.6000 x 2200 |
| Ask | 3.8100 x 1800 |
| Day's Range | 3.6400 - 4.1500 |
| 52 Week Range | 1.4100 - 6.1370 |
| Volume | 10,159 |
| Avg. Volume | 37,447 |
| Market Cap | 75.687M |
| Beta (5Y Monthly) | 2.45 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0250 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks Small Cap Research
EPIX: EPI-7386 IND Filed…
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT IND for EPI-7386 Filed On March 31, 2020, ESSA Pharma Inc. (NASDAQ:EPIX) announced that it submitted an Investigation New Drug (IND) application for EPI-7386, the company’s lead clinical candidate. The company is planning to conduct a Phase 1 clinical trial of EPI-7386 in patients with metastatic castration-resistant prostate
- PR Newswire
ESSA Pharma Submits IND for EPI-7386 for Prostate Cancer and Provides Business Update
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate its lead clinical candidate, EPI-7386, in a Phase 1 clinical study for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
- ACCESSWIRE
Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies
NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March ...
- Simply Wall St.
ESSA Pharma (CVE:EPI) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
- PR Newswire
ESSA Pharma Inc. Reports Results of Annual General and Special Meeting of Shareholders
ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on February 27, 2020 in Vancouver, British Columbia, Canada (the "Meeting").
- Zacks Small Cap Research
EPIX: IND Filing for EPI-7386 in 1Q20…
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Additional Preclinical Data Presented on EPI-7386 On February 13, 2020, ESSA Pharma Inc. (NASDAQ:EPIX) announced additional preclinical data was presented at the 2020 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium (the poster can be found here ) for its lead clinical candidate EPI-7386, which is part
- CNW Group
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2019
- CNW Group
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
ESSA Pharma Announces Multiple Abstracts Accepted for Presentation at Upcoming Medical and Scientific Symposia
- Zacks Small Cap Research
EPIX: Phase 1 Clinical Trial for EPI-7386 to Initiate in 1Q20…
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update ESSA Pharma Inc. (EPIX) is a biopharmaceutical company developing treatments for prostate cancer that is no longer responding to current therapies. The company is developing a series of compounds (‘anitens’) that disrupt the androgen receptor (AR) signaling pathway through a unique mechanism of action that targets
- Insider Monkey
Hedge Funds Have Never Been This Bullish On ESSA Pharma Inc. (EPIX)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- PR Newswire
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2019
ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX, TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal year ended September 30, 2019. All references to "$" in this release refer to United States dollars, unless otherwise indicated.
- GlobeNewswire
Janpix, Inc. Announces Appointment of Sanford (Sandy) Zweifach as Executive Chairman to its Board of Directors
Janpix, Inc., a privately-held biopharmaceutical company dedicated to the discovery and development of inhibitors/degraders of Signal Transducer & Activator of Transcription (STAT) proteins for oncological indications, announced today the appointment of Sanford Zweifach as the Company’s Executive Chairman of the Board of Directors. Mr. Zweifach brings to Janpix almost 30 years of experience in senior executive roles in the life sciences industry, with a focus in corporate partnering, business development, operations, private and public investing, and capital raising.
- Simply Wall St.
How Many ESSA Pharma Inc. (CVE:EPI) Shares Did Insiders Buy, In The Last Year?
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- Newsfile
Encode Ideas, L.P. Announces the Initiation of Research Coverage on ESSA Pharma, Inc.
Dover, Delaware--(Newsfile Corp. - November 11, 2019) - Encode Ideas, L.P. Initiates Research on ESSA Pharma, Inc. (NASDAQ: EPIX). The full research publication is available here and available on our website at www.encodelp.com. A summary follows:Encode Ideas, L.P., a healthcare focused research firm, announced today it is initiating coverage on ESSA Pharma, Inc, (NASDAQ: EPIX) as a high conviction investment idea. ESSA is developing a new class of prostate cancer drugs, known as ...
- CNW Group
ESSA Pharma Grants Stock Options
HOUSTON and VANCOUVER , Oct. 30, 2019 /CNW/ - ESSA Pharma Inc. (TSX-V: EPI; Nasdaq: EPIX) ("ESSA" or the "Corporation") announced that, pursuant to its stock option plan, it has granted incentive stock options to non – executive members of the Corporation's board of directors to purchase up to an aggregate of 225,000 common shares in the capital of the Corporation (the "Common shares"). The stock options will vest in 36 equal monthly instalments, with the first instalment vesting on the one-month anniversary of the grant date.
- PR Newswire
ESSA Pharma Presents Data on EPI-7386 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
TSX-V: EPI), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today in Boston will present new preclinical data on ESSA's lead Investigational New Drug ("IND") candidate at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. In an oral poster presentation titled, "Treatment of castrated resistant prostate cancer, with EPI-7386, a second generation N-terminal domain androgen receptor inhibitor", further preclinical characterization of EPI-7386 will be presented.
- PR Newswire
ESSA Announces Changes to its Board of Directors
VANCOUVER and HOUSTON, TX, Oct. 18, 2019 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (TSX-V: EPI, NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announces that Ari Brettman has been appointed to the board of the directors of the Company (the "Board") pursuant to a nomination right granted to Clarus Lifesciences III, L.P., now managed by Blackstone Life Sciences.
